Supporting access to eflornithine

This Schedule provides time-limited funding to states and territories (States) to reimburse the cost of purchasing and transporting the medicine eflornithine (otherwise referred to as Difluroromethylornithine or DFMO) for eligible patients.

Topic(s)
Health
Department/Agency
Health
State/Territory
NSW
VIC
Total funding
$20.00m
Agreement type
FFA - Health
Start date
18 December 2024
End date
30 June 2025
Expired agreement
No